
Opinion|Videos|May 22, 2024
FDA Approves Sotatercept for Pulmonary Arterial Hypertension
Author(s)Marius Hoeper, MD
Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.
Advertisement
Video content above is prompted by the following question(s):
- What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
- Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
- Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
3
Rheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive Disease
4
Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD
5